

The Simultaneous Effects of some Herbal Mixtures on Methimazole Medicine for Thyroid Treatment

Ahmad Putra ¹, Sara Riahi ^{2*}

Department of Cell and Molecular Biology, Universiti Putra Malaysia, Serdang, Malaysia
Department of Biology, Payam Noor University, Tehran, Iran

Received: 10 January 2018

Accepted: 07 February 2018

Published: 19 February 2018

Abstract

Several herbs and herbal products have been recommended to promote a healthy thyroid regulation. Medicinal plants and natural products represent one of the most popular alternative treatments. The present study focuses the anti-thyroid activity in *Moringaoleifera* Lam in methimazole induced hypothyroidism in female albino rats. *Moringaoleifera* were collected from the surrounding area of thanjavur district, traditionally the plant is used as antispasmodic, stimulant, expectorant and diuretic. Methimazole inhibits the enzyme thyroperoxidase, which normally acts in thyroid hormone synthesis by oxidizing the anion iodine (I⁻) to iodine (I₀), facilitating iodine's addition to tyrosine residues on the hormone precursor thyroglobulin, a necessary step in the synthesis of triiodothyronine (T₃) and thyroxine (T₄). The aim of the current study was to evaluate property of anti thyroid on Siddha medicinal plant as well as natural product by using previous events.

Keywords: Hypothyroidism; TSH; T₃; T₄; methimazole;

How to cite the article:

S. Heidary, A. Riahi, *The Simultaneous Effects of some Herbal Mixtures on Methimazole Medicine for Thyroid Treatment*, Medbiotech J. 2018; 2(1): 111-116, DOI: 10.22034/mbt.2018.60975

1. Introduction

The thyroid gland is unique among the endocrine organs in two important ways: (1) it maintains a large store of hormone, and (2) it requires iodide for hormone synthesis (Greenspan & Forsham, 1983). Thyroid hormone synthesis is seen on an individual thyroid follicular cell (Boron and Boulpaep, 2003). Thyroglobulin is synthesized in the rough endoplasmic reticulum and follows the secretory pathway to enter the colloid in the lumen of the thyroid follicle by exocytosis. Meanwhile, a sodium-iodide (Na/I) symporter pumps iodide (I⁻) actively into the cell, which previously has crossed the endothelium by largely unknown mechanisms. This iodide enters the follicular lumen from the cytoplasm by the transporter pendrin, in a purportedly passive manner (Bernard A Rousset, 2007).

Fabrication of thyroid hormones is conducted by the enzyme thyroid peroxidase, an integral membrane protein present in the apical (colloid-facing) plasma membrane of thyroid epithelial cells. Thyroid peroxidase catalyzes two sequential

reactions (i) Iodination of tyrosines on thyroglobulin (also known as "organification of iodide") and (ii) Synthesis of thyroxine or triiodothyronine from two iodotyrosines. Through the action of thyroid peroxidase, thyroid hormones accumulate in colloid, on the surface of thyroid epithelial cells. Remember that hormone is still tied up in molecules of thyroglobulin the task remaining is to liberate it from the scaffold and secrete free hormone into blood. Thyroid hormones: triiodothyronine, thyroxine (T₃ and T₄) are produced by the follicular cells of the thyroid gland and are regulated by TSH made by the thyro-tropes of the anterior pituitary gland. The effects of T₄ in vivo are mediated via T₃ (T₄ is converted to T₃ in target tissues). T₃ is 3-to 5 fold more active than T₄. Thyroxine (3, 5, 3', 5'-tetraiodothyronine) is produced by follicular cells of the thyroid gland. It is produced as precursor thyroglobulin (this is not the same as TBG), which is cleaved by enzymes to produce active T₄ (Erica et al., 2004).

In the blood, T₄ and T₃ are partially bound to thyroxinebinding globulin (TBG), transthyretin, and albumin. Only a very small fraction of the circulating

hormone is free (unbound) T4 0.03% and T3 0.3%. Only the free fraction has hormonal activity. As with the steroid hormones and retinoic acid, thyroid hormones cross the cell membrane and bind to intracellular receptors ($\alpha 1$, $\alpha 2$, $\beta 1$ and $\beta 2$), which act alone, in pairs or together with the retinoid X-receptor as transcription factors to modulate DNA transcription (Bowen, 2000).

1.1 Hormonal changes

The main hormonal changes associated with female hypothyroidism. Hypothyroid women have decreased rates of metabolic clearance of androstenedione and estrone and exhibit an increase in peripheral aromatization (Redmond, 2004 and Longcope et al., 1990). The $5\alpha/\beta$ ratio of androgen metabolites is also decreased in hypothyroid women, and there is an increase in excretion of 2-oxygenated estrogens (Gallagher et al., 1966). Concentrations of both total testosterone and E2, but their unbound fractions are increased. Alterations in steroid metabolism disappear when a euthyroid state is restored (Gordon and Southren, 1977). Gn levels are usually normal (Larsen et al., 1998). However, blunted or delayed LH response to GnRH has been reported in some hypothyroid women (Marino et al., 2006). When there is a delayed LH response, serum PRL concentration may be increased, and this may be due to hypothalamic TRH increasing both TSH and PRL secretion. Galactor-rheamay also occurs, but these disturbances disappear usually after T4 administration (Honbo et al., 1978).

1.2 Hypothyroidism

Hypothyroidism is a very common condition. It is estimated that about 2% of adult women and about 0.1-0.2% of men have clinical hypothyroidism, while the prevalence of subclinical disease is more frequent, up to 9% of adult population (Canaris et al., 2000; Danese et al., 1996; Vanderpump et al., 1995). The incidence however increases with age (Bharaktiya, 2011). The prevalence of hypothyroidism in newborns (congenital hypothyroidism) is about 1:3500 (LaFranchi, 1999). The prevalence and incidence of thyroid disorders is influenced primarily by sex and age. Thyroid disorders are more common in women than men, and in older adults compared with younger age groups. The prevalence of unsuspected overt hyperthyroidism and hypothyroidism are both estimated to be 0.6% or less in women, based on several epidemiologic studies. Age is also a factor; for overt hyperthyroidism, the prevalence rate is 1.4% for women aged 60 or older and 0.45% for women aged 40 to 60. For men more than 60 years of age, the prevalence rate of hyperthyroidism is estimated to be 0.13%. A similar pattern is observed for the prevalence rate of hypothyroidism. The prevalence

rate of overt hypothyroidism is 2% for women aged 70 to 80, 1.4% for all women 60 years and older, and 0.5% for women aged 40 to 60. In comparison, the prevalence rate of overt hypothyroidism is 0.8% for men 60 years and older. The estimated annual incidence of hyperthyroidism for women ranges from 0.36 to 0.47 per 1,000 women, and for men ranges from 0.087 to 0.101 per 1,000 men. In terms of hypothyroidism, the estimated incidence is 2.4 per 1,000 women each year. Overt thyroid dysfunction is uncommon in women less than 40 years old and in men <60 years of age (Jack DeRuiter, 2002).

1.3 Collection of the Plant Material

Fresh plant sample of *Moringaoleifera* leaves were collected from various parts of Thanjavur district. The leaves were washed, shade dried, powdered and the crude powder of *Moringaoleiferain* water suspension was administered (P.O) to the experimental rats at the dose of 100mg/100g body weight of the rats.

1.4 Animals and Treatment

Female albino rats of 8 – 10 weeks of age weighing between 100 and 120g were used for this present thyro-toxicity study. The animals were purchased from Sri Venkateswara Enterprises (Ltd), Bangalore and housed in polypropylene cages. The animals were acclimatized under laboratory conditions. All experiments were performed according to the norms of the local ethical committee. Animals were provided with normal rat's feed and normal water ad libitum. Animals were divided into three groups of six animals. Group I: normal animals provided with usual rat feed and water. Group II: as control animals provided with rat feed and water along with 40mg/kg methimazole in 100ml distilled water and the Group III as Drug treated animals provided with rat feed and water along with methimazole and crude powder of *Moringaoleiferain* water suspension and the drug followed by it.

1.5 Collection of Blood Samples

At the end of treatment, animals were fasted overnight, anaesthetized with ether and sacrificed by cervical decapitation. Blood was drawn and the serum was separated for biochemical analysis.

1.6 Biochemical Studies

Thyroid protective activity was done by assessing the significant changes in body weight, Serum T triiodothyronine thyroxine TSH was determined using ELISA kit method. Albumin level was measured spectrometrically at 600nm and total protein by biuret method a blue purple coloured complex with absorbance at 550nm. Cholesterol estimated by Siedel method and Triglycerides were estimated Friedman and Young method by

colorimetric kit method. Lipid peroxide content was assayed by thio-barbituric acid method, catalase estimated colorimetrically. Transaminases activities were estimated by Reitman and Frankel method and which was measured spectrometrically. The acid phosphatases was estimated and the absorbance was read at 405nm. Mean values standard were calculated for all the values carried out (Fisher, 1950).

2. Results and Discussion

Methimazole (1-methyl-3H-imidazole 2-thione) is an antithyroid drug, methimazole also known as Tapazole or Thiamazole or MMI, and part of the thioamide group. Like its counterpart propylthiouracil, a major side effect of treatment is agranulocytosis. Methimazole molecular formula is C₄H₆N₂S. Methimazole inhibits the enzyme thyroperoxidase, which normally acts in thyroid hormone synthesis by oxidizing the anion iodine (I⁻) to iodine (I₀), facilitating iodine's addition to tyrosine residues on the hormone precursor thyroglobulin, a necessary step in the synthesis of triiodothyronine (T₃) and thyroxine (T₄) (Nakamura, 2007).

Table 1. Anti-thyroid effect of Moringaoleifera on T₃, T₄, TSH.

Group	Dose	T ₃ ng/ml	T ₄ µg/dl	TSH µ/u/ml
Normal	Saline	115.3±5.76	6.41±0.72	3.56±0.256
Control Methimazole treated	40mg/kg	80.76±4.84	5.21±0.22	9.84±0.850
Moringaoleiferatreated	100mg/kg	95.6±7.64	7.35±0.44	7.91±0.535

Each values is the Mean ± SEM of six animals statistically significant from control Table 1 represents the serum level of normal animals in T₃, T₄ and TSH has 115.3ng/ml, 6.41µg/dl and 3.56µ/u/ml. After the induction of hypothyroidism with methimazole (40mg/kg) in thyrotoxic animals, it was found that there was a decrease in T₃ and T₄ by 80.76ng/ml and 5.21 µg/dl and the TSH level was increased to 9.84 µ/u/ml than the normal level. After the treatment with Moringaoleiferac rude powder at the dose of 100mg/dl, the serum T₃ and T₄ level was increased to 95.6ng/ml and 7.35 µg/dl and the TSH level was decreased to 7.91 µ/u/ml from the untreated control animal respectively and the difference was found as 18.37% for T₃, 41.07% for T₄ and 19.61% for TSH.

The active thyroid hormone, T₃, is one of the most powerful molecules in the human body, affecting every system, every tissue of the body and every aspect of our well-being and health. It increases the mitochondrial energy production (Wrutniak-Cabello et al., 2001 and Lebon et al., 2001).

Thyroid hormones, thyroxine (T₄), and triiodothyronine (T₃) play an important role in all major metabolic pathways. They regulate the basal energy expenditure through their effect on protein,

carbohydrate, and lipid metabolism. This might be a direct effect or an indirect effect by modification of other the untreated control animal and the difference was found as 14.79% for total protein, 12.36% for albumin, 27.27% for cholesterol and 9.5% for TGL.

Concentrations below the reference range usually reflect low albumin concentration, for instance in liver disease or acute infection. Rarely, low total protein may be a sign of immunodeficiency. Normally T₃ is bound loosely by serum proteins and hence diffuse much more rapidly into the tissues. Also the levels of cholesterol and triglycerides will be elevated the impact of subclinical hypothyroidism on lipid parameters is less well-defined. After the 30 days of the treatment with Moringaoleifera against the methimazole the cholesterol and (BrainKim, 2008).

The result of this study shows the significant hypothyroidism induced by methimazole was evidenced by decrease in serum T₃ and T₄ secretion due to thyro-necrosis. The administration of crude powder of Moringaoleifera for 30 days was found able to treat and protect thyroid cell or follicles damage against methimazole induced hypothyroidism.

The TSH level is not a measure of thyroid hormone sufficiency in any given patient, either untreated or treated; reliance on the TSH produces both under and over-diagnosis and under treatment. Dysfunctional central hypothyroidism with a normal TSH may be more common than primary hypothyroidism, and TSH-normalizing T₄ therapy neither normalizes T₃ levels nor restores euthyroidism. The TSH test is useful only for investigating the cause of clinically-diagnosed hypothyroidism. TSH test as the best screening test for the diagnosis of primary hypothyroidism and the best guide for its treatment (Garber et al., 2012). If the TSH is elevated, it is a compensatory mechanism; the increased stimulation of the dysfunctional thyroid gland may indeed work to maintain thyroid levels and effects. The TSH response to response to low FT₄ levels declines by 80% between ages of 20 and 80 (Carle et al., 2007).

The term myxedema was formerly used as a synonym for hypothyroidism. It is now well known that hypothyroidism is a graded phenomenon, including clinical manifestations (overt hypothyroidism) to asymptomatic states known as subclinical hypothyroidism (Evered & Hall, 1972). Subclinical thyroid dysfunction may be defined as an elevated TSH concentration in an asymptomatic patient with a normal serum free thyroxine concentration. It is a common condition affecting 6-17% of the general population (Helfand, 2004). Moreover, subclinical hypothyroidism may progress to overt hypothyroidism. The rate of progression is higher with the concomitant

presence of thyroperoxidase antibodies or higher levels of TSH. Thus the result shows the decreased level of Thyroid Stimulating Hormone (TSH) after the induction of Moringaoleifera in hypothyroidism induced rats.

In table 2, the serum level of the normal animals has, 5.76g/dl of total protein, 5.94mg/g serum albumin, 58.62 mg/dl of cholesterol and 37.97mg/dl of TGL. After the induction with methimazolethyrotoxic animals shows that there was an increase by 5.88g/dl of total protein, 7.60mg/g of albumin, 75.86mg/dl of cholesterol and 103.5mg/dl of TGL than the normal level. After the treatment with Moringaoleiferacrude powder at the dose of 100mg/dl, the serum total protein level was increase to 6.75g/dl and decrease serum level in albumin was 6.66mg/g, 55.17mg/dl of cholesterol and 64.2mg/dl from

Table 2. Anti-thyroid effect of Moringaoleiferaon Total Protein, Albumin, Cholesterol and TGL.

Group	Dose	Total protein g/dl	Albumin mg/g	Cholesterol mg/dl	TGL mg/dl
Normal	Saline	5.76±0.341	5.94±0.421	58.62±5.27	57.1±3.42
Control Methimazole treated	40mg/kg	5.88±0.317	7.60±0.342	75.86±4.95	103.5±6.85
Moringaoleiferatreated	100mg/kg	6.75±0.337	6.66±0.439	55.17±4.41	64.2±3.85

Each values is the Mean ± SEM of six animals statistically significant from control Thyroid hormones are associated with the oxidative and anti-oxidative status of the organism. Depression of metabolism due to hypothyroidism has been reported to decrease oxidant production and thus protects tissues against oxidant damage. The biological oxidative effects of free radicals on lipids, proteins, and DNA are controlled by a spectrum of antioxidants.

Enzymatic protection against reactive oxygen species (ROS) and the breakdown products of peroxidized lipids and oxidized protein and DNA are provided by several enzyme systems LPO and catalase (CAT) (Serdaret al., 2006). SOD catalyzes the dismutation of the superoxide anion into hydrogen peroxide (H₂O₂), which is then deactivated to water (H₂O) by catalase or glutathione peroxidase (GPx) (Das and Chainy, 2004 and Senthilet al., 2004)

Each values is the Mean ± SEM of six animals statistically significant from control Table 3 refers the normal animals have, 1.4nMDA/ml as the serum level of Lipid peroxidation, 58.6 H₂O₂decompose/mg protein of serum catalase, After the induction of hyothyroidism, it was found that there was an increase by 1.63nMDA/ml in LPO and 75.8 H₂O₂

decompose/mg protein in catalase, than the normal level. After the treatment with Moringaoleiferacrude powder at the dose of 100mg/dl, the serum LPO level was reduced to 1.51nMDA/ml and 32.2 H₂O₂ decompose/mg protein of catalase from the

untreated control animal and the difference was found as 7.36% for LPO and 23.15% for catalase.

The disturbance of antioxidant- oxidant balance and excessive production of free radicals increase ROS concentration, which can damage cell structures, a phenomenon known as oxidative stress. ROS mediated oxidative damage play a major role in pathogenesis of endothelial dysfunction and oxidation of lipids. Because of the decreased metabolic rate in hypothyroidism, free radical production is expected to be reduced. Additionally, excessive levels of TSH, which can be seen in primary hypothyroidism, were shown to cause increased production of oxidants.

Table 3. Anti-thyroid effect of Moringaoleiferaon LPO, Catalase, AST, ALT.

Group	Dose	LPO	Catalase
		nMDA/ml	H ₂ O ₂ decompose/mg protein
Normal	Saline	1.4±0.056	58.0±4.06
Control Methimazole treated	40mg/kg	1.63±0.081	41.9±1.84
Moringaoleiferatreated	100mg/kg	1.51±0.090	32.2±1.77

ALP	AST	ALT
U/l	U/l	U/l
165.84±9.28	133.32±8.65	233.31±10.49
193.48±11.22	166.65±7.03	166.65±8.33
165.84±9.36	99.99±4.49	133.32±9.99

In the estimation of Transaminase and Phosphatase, the normal animals have 165.84U/L, as the serum level of alkaline phosphatase, 233.31U/L of alanine amino transaminase and 133.32U/L aspartate aminotransferase. When comparing with control treated with methimazole shows an increase by 193.48U/L of ALP, 166.65U/L level of AST and decreased level of ALT by 193.48U/L than the normal level. After the treatment with Moringaoleiferacrude powder at the dose of 100mg/dl, the serum level was decreased to 165.84U/L in ALP, 133.32U/L in ALT and 99.99U/L in AST and from the untreated control animal and the difference was found as 14.28% for ALP, 20% for ALT and 40% for AST.

Thyroid hormones regulate Basal Metabolic Rate (BMR) and calorogenesis in tissues, including hepatocytes and thereby modulate hepatic function. The liver in turn metabolizes the thyroid hormones and regulates their systemic endocrine effect. Raised serum transaminase and phophatse (alkaline phosphatase) activities in absence of any overt liver dysfunction can therefore be attributed to primary thyroid dysfunction. The aim of this study is to assess the impairment in liver function by estimating serum Aspartate Transaminase (AST) and Alanine Transaminase (ALT) in experimental rats with hypothyroidism.

A complex relationship exists between the thyroid gland and the liver in both health and disease. The thyroid status depends not only on thyroxine secretion but also on normal thyroid hormone metabolism. Normal thyroid function, which is essential for normal growth, development and

regulation of energy metabolism within cells, is dependent on a normal functioning thyroid and liver axis. After the treatment of MO against the methimazole induced hypothyroidism after 30 days it shows significant activity in the level of transaminase and phosphatase.

2.1 Phytochemical analysis of *Moringaoleifera*

In the present study, the phytochemical analysis of ethanolic extract of *moringaoleifera* showed the presence of alkaloids, flavonoids, phenol, tannins, saponins and absence of terpenoids, coumarines, quinines, steroid compound. The significant hepatoprotective, hypothyroidism, cardioprotective and antioxidant effect of *Moringaoleifera* may be presence of phyto-constituents of the Siddha medicinal plant.

The thyro-protective effects of *Moringaoleifera* crude powder may be due to the activity of the phyto-constituents in the leaves contain fifteen components. The major compounds were hexadecanoic acid, Ethyl palmitate, Palmitic acid ethyl ester, 2, 6-Dimethyl-1, 7-octadiene-3-ol, 4-Hexadecen-6-yne, 2-hexanone, 3-cyclohexyliden-4-ethyl-E2Dodecenyacetate, Hioleic safflower oil, Safflower oil present which might have exerted the protection against the peroxidative damage and the subsequent enzyme activities as observed. Further studies are suggested on the isolation of marker compounds and phytoconstituents of the *Moringaoleifera* and their thyro-protective activity in human (Kumar and Pari, 2002).

3. Conclusion

Thyroid disease, namely hypothyroidism and hyperthyroidism, constitutes the most common endocrine abnormality in recent years, diagnosed either in subclinical or clinical form. Thyroid disease is associated with various metabolic abnormalities, due to the effects of thyroid hormones on nearly all major metabolic pathways. Thyroid gland controls the how the body uses energy makes proteins and controls how sensitive the body is to other hormones. In the present investigation the methimazole induced hypothyroidism in experimental animals show the involvement of oxidative stress and suggestive cellular damage in thyroid gland.

There was an increased activity in catalase and lipid peroxidation produced free radicals. This oxidative stress finally damages the follicles and cells in the thyroid gland. In case of high levels of thyroid stimulating hormone (TSH) values, there is a linear increase in cholesterol, , and TGLs. Lipidprofile concentrations especially the concentrations of cholesterol in hypothyroidism may leads to cardiovascular risk too. So, determination of serum levels of thyroid profile is recommended for further studies in human. There was an increase in serum

showing the impairment of thyroid function probably as the result of hypothyroidism, increase mobilization of plasma cholesterol and triglycerides and stimulate fatty acid and cholesterol degradation. The oral administration of crude powder of *Moringaoleifera* for 30 days was able to protect the cellular damage and thyroid function and activation of antioxidant enzymes. The drug administration was able to protect the thyroid dysfunction and hormonal changes as evidenced by the inhibition of the activity of phosphatases and transaminases. The study also shows the significant efficacy of *Moringaoleifera* in the treatment of hypothyroidism was also evidenced by increase in raised serum transaminase activities in absence of any overt liver dysfunction can therefore be attributed to primary thyroid dysfunction. Further studies, are needed to identify the chemical constituents of the plant *Moringaoleifera* that may be responsible for the Thyroid protective activity.

References

1. Bharaktiya. SIn: Griffing GT, ed. Hypothyroidism, 2011; Available for
2. <http://emedicine.medscape.com/article/122393overview>
3. Boron WF, Boulpaep E. "Chapter 48: "synthesis of thyroid hormones"". Medical Physiology: A Cellular and Molecular Approach. Elsevier/ Saunders. 2003; 4160-2328-3
4. Bowen. R. "Thyroid Hormone Receptors". Colorado State University. 2015; Retrieved 22 February
5. Brian Kim. Thyroid Hormone as a Determinant of Energy Expenditure and the Basal Metabolic Rate. *Thyroid.*, 2008; 18(2): 141-144. doi:10.1089/thy.2007.0266.
6. Canaris GJ, Manowitz NR, Mayor G. The Colorado thyroid disease prevalence study. *Arch Intern Med*, 2000; 160(4), 526-534.
7. Carlé A, Laurberg P, Pedersen IB, Perrild H, Ovesen L, Rasmussen LB, Jorgensen T, Knudsen N. Age Modifies the Pituitary TSH Response to Thyroid Failure. *Thyroid*. Feb 2007; 17(2):139-44.
8. Carle TL, Ohnishi YN, Ohnishi YH, Alibhai IN, Wilkinson MB, Kumar A, Nestler EJ. *Eur J Neurosci*. May 2007; 25(10):3009-19.
9. Danese MD, Powe NR, Sawin CT, Ladenson PW. Screening for mild thyroid failure at the periodic health examination: a decision and cost-effectiveness analysis. *JAMA.*, 1996; 276: 285-92.
10. Das K, Chainy GBN. Thyroid Hormone influences antioxidant defense system in adult rat brain. *Neurochemical Research.*, 2004; 29(9):1755-1766.
11. Erica A.; Pescovitz, Ora Hirsch. Pediatric endocrinology: mechanisms, manifestations and

- management. Hagerstown, MD: Lippincott Williams & Wilkins. 2004;ISBN 0-7817-4059-2.
15. Fisher A. In statistical methods for research worker. Oliver and Boyd, Edinburgh. 1950.
 16. Friedman and Young. Effects of disease on clinical laboratory tests, 4th ed. AACCPress, 2001.
 17. Gallagher TF, Fukushima DK, Noguchi S, Fishman J, Bradlow HL, Cassouto J, Zumoff B, Hellman L. Recent studies in steroid hormone metabolism in man. *Recent Prog Horm Res.*, 1996; 22:283-303
 18. Garber JR, Cobin RH, Gharib H, Hennessey JV, Klein I, Mechanick JI, Pessah-Pollack R, Singer PA, Woeber KA. Clinical Practice Guidelines for Hypothyroidism in Adults: Co-sponsored by American Association of Clinical Endocrinologists and the
 19. American Thyroid Association. *Endocr Pract.*, 11, 1207. <https://www.aace.com/files/final-file-hypoguidelines.pdf>; 2012.
 20. Gordon GG, Southren A. Thyroid-hormone effects on steroid-hormone metabolism. *Bull NY Acad Med*; 1977; 53: 241-259
 21. Greenspan SL, Greenspan FS. The effect of thyroid hormone on skeletal integrity. *Ann Intern Med.*, 1999; 130:750-758.
 22. Helfand M. U.S. Preventive Services Task Force. Screening for subclinical thyroid dysfunction in nonpregnant adults: a summary of the evidence for the U.S. Preventive Services Task Force. *Ann Intern Med.*, 2004; 140(2):128-141.
 23. Honbo KS, van Herle AJ, Kellett KA. Serum prolactin levels in untreated primary hypothyroidism. *Am J Med.*, 1978; 64:782-787
 24. Jack DeRuiter. Thyroid hormone tutorial: thyroid pathology, Endocrine Module (PYPP 5260), Thyroid Section, Spring, 2002.
 25. Kumar A and Pari L. Antioxidant action of
 26. Moringaoleifera Lam (drumstick) against antitubercular drugs induced lipid peroxidation in rats. *Journal of Medicinal Food.*, 2003;6, 255-259.
 27. LaFranchi S. Congenital hypothyroidism: etiologies, diagnosis, and management. *Thyroid.* 1999; Vol.9., N.7, pp. 735-40.
 28. Larsen PR, Davies TF, Hay ID. The thyroid gland. In: Wilson JD, Foster DW, Kronenberg HM, Larsen PR, eds. *Williams text book of endocrinology.* 9th ed. Philadelphia: WB Saunders, 1998; 389-515
 23. Longcope C, Abend S, Braverman LE, Emerson CH. Androstenedione and estrone dynamics in hypothyroid women. *J Clin Endocrinol Metab.*, 1990; 70:903-907
 29. Marino M, Chiovato L, Pinchera A. Graves' disease. In: DeGroot LJ, Jameson JL, eds. *Endocrinology.* 5th ed. Philadelphia: Elsevier Saunders, 2006; 1995-2028
 30. Nakamura H, Noh JY, Hoh K, Fukata S, Miyauchi A, Hamada N. Comparison of methimazole and propyl thio uracil in patients with hyperthyroidism caused by grave's disease. *The journal of clinical Endocrinology and metabolism.*, 2007; 92(6):2157-62.
 31. Redmond GP. Thyroid dysfunction and women's reproductive health. *Thyroid.*, 2004; 14(Suppl 1):S5-S15
 27. Reitman. Sand S Frankel. *Am J Clinpathol.*, 1957; 28: 56-63.
 32. Rousset B, Dupuy C, Miot F, et al. Chapter 2 Thyroid Hormone Synthesis and Secretion. [Updated 2015 Sep 2]. In: De Groot LJ, Chrousos G, Dungan K, et al., editors. *Endotext* [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000-. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK285550/>
 33. Senthil S, Veerappan RM, Ramakrishna Rao M, Pugalendi KV. Oxidative stress and antioxidants in patients with cardiogenic shock complicating acute myocardial infarction. *Clinica Chimica Acta.*, 2004; 348(1-2):131-137.
 34. Serdar Z, Aslan K, Dirican M, Sarandöl E, Yeşilbursa D, Serdar A. Lipid and protein oxidation and antioxidant status in patients with angiographically proven coronary artery disease. *Clinical Biochemistry.*, 2006; 39(8):794-803.
 35. Siedel, *J. Clin. chem.*, 1983; 29, 1075.
 36. Tunbridge WM, Evered DC, Hall R, Appelton D, Brewis M, Clark F et al. The spectrum of thyroid disease in a community: the Wickham survey. *Clinical Endocrinology.*, 1977; 7: 481-493.
 37. Vanderpump, M.P., Tunbridge, W.M., French, J.M. et al. The incidence of thyroid disorders in the community: a twenty year follow-up of the Wickham
 38. Survey. *Clinical Endocrinology (Oxford)*, 1995; 43, 55- 68.s
 39. Wrutniak-Cabello C, Casas F, Cabello G. Thyroid hormone action in mitochondria. *J Mol Endocrinol.* Feb, 2001; 26(1):67-77.